These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36998609)

  • 1. The cholesterol-lowering effect of statins is modified by
    Tornio A; Bigossi M; Siddiqui MK; Kennedy G; Melhem A; Chourasia MK; Maroteau C; Pola R; Chasman DI; Doney ASF; Palmer CNA
    Front Pharmacol; 2023; 14():1090010. PubMed ID: 36998609
    [No Abstract]   [Full Text] [Related]  

  • 2. Common Statin Intolerance Variants in
    Melhem AL; Chourasia MK; Bigossi M; Maroteau C; Taylor A; Pola R; Dawed AY; Tornio A; Palmer CNA; Siddiqui MK
    Front Genet; 2021; 12():713181. PubMed ID: 34659336
    [No Abstract]   [Full Text] [Related]  

  • 3. A common missense variant of LILRB5 is associated with statin intolerance and myalgia.
    K Siddiqui M; Maroteau C; Veluchamy A; Tornio A; Tavendale R; Carr F; Abelega NU; Carr D; Bloch K; Hallberg P; Yue QY; Pearson ER; Colhoun HM; Morris AD; Dow E; George J; Pirmohamed M; Ridker PM; Doney ASF; Alfirevic A; Wadelius M; Maitland-van der Zee AH; Chasman DI; Palmer CNA;
    Eur Heart J; 2017 Dec; 38(48):3569-3575. PubMed ID: 29020356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
    Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
    Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus.
    Castaño G; Fernández L; Mas R; Illnait J; Mesa M; Fernández JC
    Clin Drug Investig; 2003; 23(10):639-50. PubMed ID: 17535079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G; Mushtaq S
    Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.
    Pareek A; Chandurkar N; Thulaseedharan NK; Legha R; Agarwal M; Mathur SL; Salkar HR; Pednekar S; Pai V; Sriram U; Khyalappa R; Parmar M; Agrawal N; Dhruv U; Saxena S
    Curr Med Res Opin; 2015 Nov; 31(11):2105-17. PubMed ID: 26371518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
    Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
    Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.
    Ur E; Langer A; Rabkin SW; Calciu CD; Leiter LA;
    Can J Cardiol; 2010 Feb; 26(2):80-6. PubMed ID: 20151053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial.
    Ghati N; Roy A; Bhatnagar S; Bhati S; Bhushan S; Mahendran M; Thakur A; Tiwari P; Dwivedi T; Mani K; Gupta R; Mohan A; Garg R; Saxena A; Guleria R; Deepti S
    Trials; 2020 Oct; 21(1):902. PubMed ID: 33126910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs.
    Herrett E; Williamson E; Brack K; Perkins A; Thayne A; Shakur-Still H; Roberts I; Prowse D; Beaumont D; Jamal Z; Goldacre B; van Staa T; MacDonald TM; Armitage J; Moore M; Hoffman M; Smeeth L
    Health Technol Assess; 2021 Mar; 25(16):1-62. PubMed ID: 33709907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CKM and LILRB5 are associated with serum levels of creatine kinase.
    Dubé MP; Zetler R; Barhdadi A; Brown AM; Mongrain I; Normand V; Laplante N; Asselin G; Zada YF; Provost S; Bergeron J; Kouz S; Dufour R; Diaz A; de Denus S; Turgeon J; Rhéaume E; Phillips MS; Tardif JC
    Circ Cardiovasc Genet; 2014 Dec; 7(6):880-6. PubMed ID: 25214527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
    Murphy WA; Lin N; Damask A; Schwartz GG; Steg PG; Szarek M; Banerjee P; Fazio S; Manvelian G; Pordy R; Shuldiner AR; Paulding C
    Circ Genom Precis Med; 2022 Jun; 15(3):e003503. PubMed ID: 35543701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.